OGT Licenses Array IP to Two More Japanese Companies

Aug 15, 2006

NEW YORK (GenomeWeb News) – Two more Japanese companies have licensed Oxford Gene Technology’s oligonucleotide microarray patents to sell arrays, OGT said today.

Bio Matrix Research, a bio venture company launched by Tokyo University of Science, will develop and commercialize products and microarrays to be marketed in Japan, the company said.

Filgen will conduct a microarray service in Japan using licensed microarrays.

The licenses will remain valid for the patents’ lifetime.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Quickly, Quickly

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Twisting the Results

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

'Right to Try' Heads Toward Law

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

This Week in Genome Research

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Featured White Papers

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

FEMTO Pulse Genomic DNA Sizing and Quality Control

Optimized NGS Library Preparation with Acoustic Liquid Handling

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun

21

Featured Webinar

Evaluation & Implementation of NGS Liquid Biopsy Assays

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.

Main menu